Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.2%

1 terminated out of 24 trials

Success Rate

94.7%

+8.2% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed with results

Key Signals

5 with results95% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (2)
P 1 (8)
P 2 (6)
P 3 (2)
P 4 (1)

Trial Status

Completed18
Recruiting3
Withdrawn2
Terminated1

Trial Success Rate

94.7%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07017777Phase 3Recruiting

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

NCT07343167RecruitingPrimary

Factors Associated With Mortality in Streptococcal Anginosus Bacteremia

NCT07085702Phase 1RecruitingPrimary

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults

NCT04841369Phase 3Completed

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

NCT04100772Phase 1Completed

Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

NCT02270944Phase 2Completed

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

NCT00598429Phase 2Withdrawn

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

NCT03055728CompletedPrimary

Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis

NCT00169481Phase 2CompletedPrimary

A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine

NCT00330642WithdrawnPrimary

Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study

NCT02052973Phase 1CompletedPrimary

Efficacy of Propolis Varnish Against Oral Biofilm

NCT01118143Not ApplicableCompleted

Oral Health Literacy Tailored Communication

NCT01412801Phase 2CompletedPrimary

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

NCT01193920Phase 1CompletedPrimary

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age

NCT00646958Phase 2Completed

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT01026558Phase 1Completed

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

NCT01030731Phase 1Completed

Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease

NCT01026740Phase 1Completed

Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers

NCT01026636Phase 1Completed

A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

NCT00299663CompletedPrimary

Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract

Scroll to load more

Research Network

Activity Timeline